The Growing Acceptance Of Healing Honey Featured
PRINCETON, N.J., June 12 /PRNewswire-FirstCall/ -- Derma Sciences (OTC Bulletin Board: DSCI), a provider of advanced wound care products, CEO Ed Quilty was a guest this morning on Canada's Business News Network, BNN. He discusses the Company's novel wound dressing, MEDIHONEY(TM) and its upcoming consumer distribution within Canada.
Gemini Award-Winning Broadcaster Linda Sims examines the use of
MEDIHONEY where antibiotics have failed against super-bugs and advanced
wounds. She also discusses current events of Derma Sciences with Mr Quilty
and where the Company is heading.
The interview can viewed via the following link.
The information in the segments contains uses that have not been cleared by the US Food and Drug Administration.
About Derma Sciences
Derma Sciences is a global manufacturer and marketer of advanced
wound-care products. Its key product, MEDIHONEY, is sold throughout the
world by Derma Sciences and Comvita New Zealand -- the licensor of the
patented honey-based technology -- and is the leading brand of honey-based
dressings for the management of wounds and burns. The product has been
shown to be effective in a variety of wounds and burns, and was recently
the focus of a large-scale randomized controlled trial on leg ulcers. Derma
has two products in development: the NIMBUS technology based line of
barrier gauze dressings, and DSC127, the company's novel angiotensin analog
for accelerated wound healing and scar reduction. The barrier technology
was licensed from Quick-Med in Q1 of 2007 and is pending its initial FDA
marketing clearance. DSC127 was licensed from The University of Southern
California in Q4 of 2007 and is entering into a Phase II study, with
anticipated initial patient enrollment to begin in Q3 of 2008. For more
information about Derma Sciences, Inc., visit its home page on the Internet
Contact: Derma Sciences Inc Allen & Caron Inc
Edward J. Quilty Rudy Barrio (US Investors)
Chairman and CEO email@example.com
(609) 514-4744 Brian Kennedy (media)
|SOURCE Derma Sciences|
Copyright©2008 PR Newswire.
All rights reserved